# China NMPA Drug Inspection - Ningxian Kangshengyuan Pharmaceutical Co., Ltd. - Qianhu

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/ningxian-kangshengyuan-pharmaceutical-co-ltd/47c7d4df-a31e-43c5-87db-7430a908c178/
Source feed: China

> China NMPA drug inspection for Ningxian Kangshengyuan Pharmaceutical Co., Ltd. published December 26, 2019. Drug: Qianhu. The Shaanxi Provincial Drug Administration published an announcement on December 26, 2019, detailing the results of its 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Shaanxi Province Drug Quality Bulletin (No. 101, 2019)
- Company Name: Ningxian Kangshengyuan Pharmaceutical Co., Ltd.
- Publication Date: 2019-12-26
- Drug Name: Qianhu
- Inspection Finding: Content determination did not meet the requirements
- Action Taken: The relevant municipal (county, district) drug regulatory authorities have taken necessary control measures and are investigating and handling the matter in accordance with relevant laws and regulations.
- Summary: The Shaanxi Provincial Drug Administration published an announcement on December 26, 2019, detailing the results of its 10th drug quality inspection for that year. This comprehensive oversight initiative aimed to reinforce drug supervision and ensure public medication safety within the province. The inspection identified ten batches of drugs from multiple manufacturers that failed to meet established quality standards.

Key manufacturers identified with non-compliant products include Shijiazhuang Chengxin Traditional Chinese Medicine Co., Ltd., Qingyang Yixiang Pharmaceutical Co., Ltd., Anguo Yuanguang Pharmaceutical Co., Ltd., Ningxian Kangshengyuan Pharmaceutical Co., Ltd., Hebei Kangbo Pharmaceutical Co., Ltd., and Hebei Qixin Traditional Chinese Medicine Granules and Slices Co., Ltd. The primary quality issues discovered pertained to drug characteristics (appearance/properties), general inspection parameters, and content determination. These deviations signify non-compliance with the stringent quality requirements stipulated in the Chinese Pharmacopoeia 2015 Edition, Part I.

Following these findings, relevant municipal and local drug regulatory departments have implemented essential control measures concerning the affected units. Further actions include conducting thorough investigations and processing these cases in accordance with pertinent legal and regulatory frameworks to ensure accountability and uphold robust drug safety standards across the province.

Company: https://www.globalkeysolutions.net/companies/ningxian-kangshengyuan-pharmaceutical-co-ltd/8689fcfc-4151-4b00-a342-098e3818a17d/